Foods derived from genetically modified animals are far from safe. They are likely to be contaminated by potent vaccines, immune regulators, and growth hormones, as well as nucleic acids, viruses, and bacteria that have the potential to create pathogens and to trigger cancer.
Prof. Joe Cummins and Dr. Mae-Wan Ho
The Codex Alimentarius Commission of the United Nations is preparing guidelines for safety assessment of foods derived from recombinant-DNA animals . Comments on the topic can be submitted before 1 October 2006 to Codex Alimentarius Commission FAO Viale delle Terme di Caracalla 00100 Rome, Italy, Fax: +39 06 5705 4593 E-mail: email@example.com Copy to:Dr. FUJII Mitsuru Counsellor, Minister's Secretariat, Ministry of Health, Labour and Welfare 1-2-2 Kasumigaseki, Chiyoda-ku 100-8916 Tokyo, Japan Fax: +81 3 3503 7965 E-mail: firstname.lastname@example.org . It is likely that the establishment of food safety assessment guidelines will be followed by an avalanche of applications for releasing genetically modified (GM) animals.
Codex distinguishes between heritable and non-heritable genetic modification of food animals. Heritable genetic modification involves genetic changes that persist in sperm and egg while non-heritable modification involves the introduction of modified genes such as vaccines into the somatic tissue of animals. Codex asks: “Are there specific food safety questions (e.g. with regard to types of vectors) that should be considered relative to the assessment of safety of food from animals containing heritable versus non-heritable traits?”
Our submission for the Institute of Science in Society provides a review of both heritable and non-heritable genetic modifications of animals for food, followed by specific comments.
A. Heritable Modifications of Food Animals
Heritable alteration or genetic modification (GM) of food animals has been achieved since the early 1980s, mostly by injecting naked DNA. Between 1 and 20 million copies of the transgene (gene to be integrated into the animal genome) are injected into the embryo pronucleus (the nucleus before fertilization) or into the egg cytoplasm, with at most about one percent of injected embryos becoming transgenic animals. The transgenes integrate randomly, though rare instances of homologous recombination with host genes may occur.
A number of different vectors have been used to deliver transgenes. Transposons (mobile genetic units capable of transferring genes) are not widely used in vertebrates. Lentivirus (lenti-, Latin for “slow”), a genus of slow viruses of the Retroviridae family characterized by a long incubation period, can deliver a significant amount of genetic information into the DNA of the host cell, and are among the most efficient gene delivery vectors. HIV (human immunodeficiency virus), SIV (simian immunodeficiency virus), and FIV (feline immunodeficiency virus) are all examples of lentiviruses that have been used successfully with farm animals such as chicken, pig and cow. They are about 50 times more efficient than DNA injection at producing transgenic animals. One problem encountered is that the long terminal repeats of the integration vector interfere with the inserted gene's promoter. Homologous recombination has been used to produce specific gene “knock outs” by replacing an active gene with an inactive one. “Knock in” refers to the integration of a foreign gene at a specific target, disrupting the target gene by inserting the transgene.
Transgenes are designed according to rules that result in gene expression in the host animal, such as the presence of at least one intron, exclusion of GC rich regions, particularly CpG rich motifs. Gene sequences called insulators are often included; these contain transcription enhancers and enhancer blockers to avoid cross talk with adjacent genes, and chromosome openers that modify histones to allow the transcription machinery to be expressed. Finally, RNAi may be used to inactivate specific genes either as heritable transgenes or as non-heritable gene treatments . A lentivirus vector based on HIV dramatically increased the efficiency of producing transgenic animals, thereby greatly reducing cost. Foetal fibroblast cells can be modified and then cloned to produce transgenic animals .
A novel approach was to transfect germ cell tissue in neonatal testis by electroporation, which was then ectopically xenografted onto the backs of nude mice (nude mice are immune deficient and tolerate grafts from mammalian tissues). The nude mice, previously castrated, produced mature transgenic sperm that functioned well in in vitro fertilization to produce transgenic farm animals. The technique has been used successfully in cattle, pigs and even humans (though without producing an actual human as yet). The technique is promoted for humans as a means of allowing men requiring irradiation cancer treatment to set aside viable sperm for in vitro fertilization [4-6].
‘Improving' the nutritional value and health benefits of livestock
Transgenic clones of cattle producing milk with higher levels of beta casein and kappa casein proteins were created . The casein fraction of milk contains four proteins in colloidal aggregates in emulsion. Kappa-casein coats the aggregates, and increasing the concentration of the protein results in smaller aggregates (a finer emulsion) and improves processing and heat stability. Beta-casein binds calcium, increasing calcium content of the milk and also improves processing. Rare natural forms of beta- and kappa- caseins were used to transform embryonic fibroblasts with as many as 84 copies of the genes integrated randomly in the genome. The fibroblasts were then used to produce clones of the cattle. Nine cows expressing the transgenes produced milk with up to 20 percent increase in beta-casein and double the level of kappa-casein. The overall health of the transgenic cattle was not discussed in any detail, let alone the health impacts of the milk used as food.
Consumers need to be alerted to a whole range of genetically modified ‘neutraceuticals', animals and animal products that are supposed to provide enhanced nutritional value.
Cloned transgenic pigs have been produced rich in beneficial omega-3 fatty acids  normally obtained by eating fish. The transgene consisted of a synthetic n-3 fatty acid desaturase from the roundworm C. elegans driven by a cytomegalovirus enhancer and chicken beta-actin promoter, accompanied by a selection marker gene for neomycin resistance. Pig foetal fibroblasts were transformed and then used to clone transgenic pigs. The transgenic pigs produced high levels of omega-3 fatty acids and a significantly reduced ratio of n-6/n-3 fatty acids. As before, the overall health of the cloned transgenic pigs was not extensively discussed, nor the health impacts of the transgenic pig used as food.
Recombinant human protein C was expressed in the milk of cloned transgenic pigs . Human protein C is an anti-coagulant found in the blood, and serves as a therapy for many disease states. Foetal pig fibroblasts were transformed with a fusion gene consisting of the mouse acidic whey protein and its promoter and terminator into which the pig protein C gene sequence had been inserted. This results in high production of human C protein. The transgenic fibroblast nucleus was cloned to produce pigs with human C protein in their milk. The transgenic pigs produced the therapeutic protein, which protected the pigs against blood clot, but with a risk of pulmonary embolism.
Pigs expressing an E. coli salivary phytase produced low phosphorus manure . Phytase increases the availability of feed phosphorous and decreases its release in manure, thereby eliminating environmental pollution by phosphorus.
Transgenic chickens expressing bacterial beta-galactosidase hydrolyze lactose in the intestine, and to use that sugar as an energy source [11, 12]. Chickens fed lactose-containing foods normally develop diarrhoea, while transgenic chickens can thrive on lactose containing feed, such as dairy products or waste products. Early chicken embryos were transformed using the spleen necrosis retrovirus vector (SNTZ) , a replication-defective vector containing neomycin resistance selectable marker under the control of a SV40 viral promoter and poly A transcription termination, and the beta-galactosidase was preceded by a nuclear-localization signal sequence. Beta-galactosidase activity was identified in the chicken's intestinal mucosa. SNTZ is an avian immunosuppressive retrovirus that infects non-replicating cells, not only of birds but of some mammals as well. It has an extraordinarily high mutation rate, and that is not a defect in the replication-deficient vector.
Transgenic fish are poised for commercial release. These will either be produced in confined land-locked ponds, fish pens in confined fjords or sounds, or released to open seas or lakes. Landlocked ponds provide protection from environmental release while fish pens are notoriously unreliable and tend to harbour sea lice or other parasites and pathogens. Release to open waters is final and irrevocable and fraught with uncertainty. It would seem most prudent to limit production of transgenic fish to landlocked ponds, to avoid or reduce the potentially deleterious impact of transgenic fish on the general environment.
Fish genes are most frequently used in producing transgenic fish, and there is a tendency to regard the transgenic fish “substantially equivalent” to the native fish even though the transgenes originate from species unable to interbr eed with the species receiving the transgene, and the Codex consultation document  acknowledges that, “transgenic expression of non-native proteins in plants may lead to structural variants possessing altered immunogenicity.”
“Substantial equivalence” has been discredited as a deceptive and useless concept  ( The Case for a GM-free Sustainable World ) that should no longer be employed in risk assessment of any GMO (see more detailed critique later). A new policy framework is needed to cope with the release of transgenic fish to the environment [14, 15].
In 1999, AquaBounty Inc. first applied to the FDA (Food and Drug Administration) in the United States to release a transgenic Atlantic salmon. AquaBounty announces that it is also developing fast growing strains of fin fish known as AquAdvantage™ fish, capable of reducing growth to maturity time by as much as 50 percent. It is expecting FDA approval in 2006 and c ommercial launch in 2009 . The transgenic Atlantic salmon contains a Chinook salmon growth hormone gene driven by the ocean pout antifreeze promoter, resulting in a dramatic increase in growth rate . Scientists have expressed concerns over the release of sexually reproducing transgenic fish; realistic models show that it can lead to the extinction of both the natural and the transgenic populations [18, 19]. AquaBounty has produced triploid transgenic Atlantic salmon supposed to be 100 percent sterile ; however, the sterility may be “leaky”, and some fertile animals have been produced [2 1] ( Floating Transgenic Fish in a Leaky Triploid Craft ) .
Transgenic Coho salmon was constructed by introducing a sockeye salmon growth hormone gene driven by a sokeye metalothionen-B promoter. The transgenic animals were hemizygous for the transgen e, being F1 animals from crosses between transgenic and normal animals. The transgenic salmon con sistently outgrew normal animals [22, 23]. Transgenic Coho fry emerged from gravel nests two weeks earlier than normal Coho, but had a highly reduced survival rate, as they suffered higher predation than the normal fry. Adult transgenic Coho survived just as well as the wild-type Coho .
A rainbow trout growth hormone (rtGH) gene was used to produce transgenic carp . DNA from a cloning vector, pRSV-2 , was introduced by microinjection into cells at an early stage of embryo development. The recombinant plasmid contained the rtGH gene driven by the long terminal repeat (LTR) from Rous sarcoma virus (RSV), and additional apparently non-functional flanking sequences of bacterial DNA. The LTR functions as an efficient recognition site for initiation of synthesis of rainbow trout growth hormone protein in transgenic carp. The transgenic carp had an altered body form and higher proportion of protein to fat than the wild-type carp, and required high histidine and lysine ratios in its diet for maximum growth .
Transgenic tilapia constructed with the ocean pout promoter driving a Chinook salmon growth hormone gene showed greatly enhanced growth . Tilapia is a tropical fish while the ocean pout is an arctic species. Heat shock induced tilapia triploids resulted in fish ovaries devoid of eggs, but the testes of rare individual fish contained mature sperm .
Transgenic mud loach was created by fusing the mud loach's beta-actin promoter to its growth hormone gene. The transgenic fish grew 35 times faster than the wild type fish, resulting in giant mud loaches that were ready for market after only 30 days .
Transgenic zebra fish have been sold in United States pet shops since 2003  ( Transgenic Fish Coming ) . The transgenic zebra fish were projected to be capable of over-wintering in US southern and south western waters . FDA allowed the release of the zebra fish because the animals did not fall into their jurisdiction. As the animals have been released, their presence in the natural environment should be monitored as a model for the release of transgenic food fish.
B. Non-heritable modifications of food animals
Non-heritable modifications of food animals include a number of applications such as DNA vaccination, transgenic probiotic bacteria as vector for vaccines and growth hormones, using RNAi (RNA interference) for epigenetic modifications, and stem cell chimeric animals whose somatic tissue but not the germ cells are transgenic. Non- heritable alterations are taking place or being implemented without full review of the impact on food and the environment, mainly because they do not fall under the rubric of genetic modification.
Naked DNA vaccines
It has been shown since the 1990s that ingested foreign DNA survives transiently in the gastrointestinal tract and enters the bloodstream of mice . Since then, naked DNA has found many applications, especially as DNA vaccines. DNA vaccines can be applied by a variety of routes including intradermal, intravenous, intramuscular, intraperitoneal, subcutaneous, sublinqual, intravaginal, intrarectal, via internasal inhalation, intranasal instillation, ocular and biolistic delivery . Gene vaccines are becoming commonplace and have the advantage of raising antibodies to a target antigen specifically . However, DNA immunization can stimulate florid local inflammation . DNA vaccines are commonly delivered in polyethyenimine complexes, where the plasmid DNA remains active in cells at least 12 days after injection .
DNA vaccines are used in both farm animals and fish, and there does not appear to be reports on whether there is any carry over of the vaccine DNA into food prepared from vaccinated animals.
Pigs have been immunized against pork tapeworms with a DNA vaccine injected intramuscularly . Pork tapeworm can be transmitted to humans.
An improved DNA vaccine for bovine herpes virus-1 was constructed using the viral gene for protein VP22 . Bovine herpesvirus 1 (BHV-1) causes several diseases in cattle worldwide , including inflammation of nose and trachea, vagina, penis, eyes, gut, and abortion. BHV-1 is also a contributing factor in shipping fever. It is spread through sexual contact, artificial insemination, and aerosol transmission.
A novel combination of recombinant DNA and recombinant protein was used to vaccinate cattle against mastitis caused by Staphylococcus aureus . The cattle were first immunized with two recombinant DNA plasmids; the first containing gene fragments of the fibronectin binding motifs joined to gene fragments of clumping factor A, the second carrying a gene for the bovine granulocyte-macrophage - colony stimulating factor gene. Pregnant heifers were immunized twice with the DNA plasmids then boosted with the recombinant hybrid protein consisting of fibronectin binding motifs joined to fragments of clumping factor A. The immunized heifers were partially protected from mastitis and illnesses after infection.
A recombinant plasmid DNA vaccine was made to control infectious bursal disease , a highly contagious viral disease of young chickens characterized by immunosuppression and mortality generally at 3 to 6 weeks of age. The vaccine plasmid contained the VP2 gene of the double stranded RNA virus driven by the human cytomegalovirus immediate early enhancer and promoter, the adenopartite leader sequence and a SV40 polyadenylation signal. The plasmid vaccine also contained a CpG oligonnucleotide adjuvant to enhance innate immunity. The combined vaccine was reported to effectively control infectious bursal disease.
A recombinant plasmid DNA vaccine was prepared to control viral hemorrhagic septicemia , a systemic infection of various salmonid and a few nonsalmonid fishes caused by a rhabdovirus (a single stranded RNA virus). The virus infection occurs in fish of any age and may result in significant mortality. The plasmid vaccine contained a recombinant glycoprotein gene from the virus; and specific antibodies against the recombinant protein were detected after vaccination.
A DNA vaccine was made to protect against Mycobacterium marinum that causes tuberculosis in fish and shellfish and cutaneous lesions in humans . The bacterium is transmitted from fish to humans. The vaccine consists of a DNA plasmid carrying the bacterial gene for a protein that binds to a secreted fibronectin. Fibronectin is a high molecular weight fish glycoprotein that binds to receptor proteins called integrins spanning the cell membrane. In addition to integrins, they also bind to extracellular matrix components such as collagen, fibrin and heparin. Vaccinated striped bass were protected from the bacterium.
Recombinant vaccine vectors
Recombinant vectors have been developed from viruses or bacteria to deliver vaccine antigens. One fundamental concern over the use of such vectors is genetic recombination involving the vectors, resulting in novel pathogens. Not only are the vectors themselves already derived from pathogens, but they also carry transgenes from other pathogens.
A Newcastle disease virus was modified to express the H5 hemagglutinin of avian influenza. Newcastle disease is a highly contagious bird disease affecting many domestic and wild avian species, and is caused by a single stranded RNA virus. Its effects are most notable in domestic poultry, which are highly susceptible to the disease with the potential for severe epidemics that impact on the poultry industry. Avian influenza is endemic to many countries, and is a threat to both commercial and wild fowl as well as to humans. The virus can change to a form that causes serious disease in humans through reassortment, mutation and recombination [42-44] ( Fowl Play in Bird Flu ; Where's the Bird Flu Pandemic? ; What Can You Believe About Bird Flu? ). The chimeric vector vaccine is expected to protect against both influenza and Newcastle disease. The vaccine was tested so far only on about 15 chickens that were examined after 10 days and judged healthy . It is clear that more extensive safety studies are needed.
A recombinant pseudorabies virus expressing a fusion protein of pig circovirus type 2 was made . Pseudorabies viral disease in swine is endemic in most parts of the world, and is caused by porcine herpesvirus 1. The name pseudorabies comes from the similarity of symptoms to rabies in dogs. Secondary hosts are infected through direct contact with swine, or via infected pork. Porcine circovirus (PCV) is a member of the virus family Circoviridae; and there are two serotypes, PCV1 and PCV2. These relatively small, non-enveloped, circular DNA viruses are quite stable in the environment and resistant to many common disinfectants. PCV2 is associated with postweaning multisystemic wasting syndrome (PMWS) in piglets, characterized by progressive loss of body condition, visibly enlarged lymph nodes, difficulty in breathing, and sometimes diarrhoea, pale skin, and jaundice. The vaccine appears to protect against both circovirus and psuedorabies virus infection, but its safety remains to be ascertained.
The use of lactic acid bacteria as vehicles to delivery antigens to immunize animals appears promising. When genetically modified, these bacteria can induce a specific local and systemic immune response against selected pathogens. Gastric acid and bile salts tolerance, production of antagonistic substances against pathogenic microorganisms, and adhesive ability to gut epithelium are other important characteristics that make these bacteria useful for oral immunization. By the same token, genetically modifying these bacteria has the potential to turn them into serious pathogens.
Lactobacillus isolated from the gastrointestinal tract of broiler chickens and selected for probiotic characteristics was genetically modified by inserting an expression cassette into the lbs gene . The transformed bacteria expressed different fluorescent cell surface proteins used as reporters of promoter function. It is possible that the same procedure can be used to construct bacteria expressing pathogen antigens as live oral vaccines to immunize broilers against infectious diseases. A number of such ora l vaccines have been successfully tested in mice but reports of vaccination of food animals are not yet available.
Using GM probiotic bacteria as vaccine vectors requires special caution. These bacteria are natural beneficial symbionts of the gastrointestinal tract, and have adapted to their human and animal hosts over millions if not billions of years of evolution. Genetically modifying them as vectors could easily turn them into pathogens pre-adapted to invade the human and animal gut . Furthermore, the gastroinstestinal tract is an ideal environment for horizontal gene transfer and recombination, the major route to creating pathogens. For these reasons, we have proposed that any genetic modification of probiotic bacteria should be banned [49, 50] ( Ban GM Probiotics ; GM Probiotic Bacteria in Gene Therapy ).
There is increasing evidence that infectious disease epidemics, such as bird flu, are created by intensive industrial farming of livestock and the globalised trade in livestock, meat and animal products  ( Fowl Play in Bird Flu ). Vaccines are risky on the whole, and cost a lot to develop; and may well not be necessary if much more effort were devoted to establishing farming practices that reduce stocking rates while improving animal welfare, nutrition and health to build up the animals' natural immunity to disease.
RNAi in epigenetic gene modification in food animals
Among the major discoveries of molecular genetics in the 1990s is RNA interference (RNAi), how very small RNA molecules - around 21 to 25 nucleotides or shorter - can inhibit expression of specific genes in all organisms  ( Subverting the Genetic Text ). RNAi regulates basic biological processes, including transition from one stage of development to another. Furthermore, RNAi is used as a form of immunity to protect the cell from invasion by foreign nucleic acids introduced by mobile genetic elements and viruses. RNAi soon found applications in human gene therapy  , as it appeared to offer the ability to shut down any chosen gene specifically without affecting any other.
But the technique hailed as “breakthrough of the year” in 2002 was found not to be so specific after all. There were substantial “off target” effects on other genes and proteins [53, 54] ( Controversy over Gene Therapy 'Breakthrough' ). In May 2006, RNAi gene therapy was found to kill mice by the dozens [55, 56] ( Gene Therapy Nightmare for Mice ). The mice died of liver failure from RNAi overload. There are reasons to believe that RNAi therapy is unsafe, because the effects are not, and cannot be specific. Numerous RNA species interfere at every level of gene function, and it is impossible to target the effects precisely because the RNA interference underworld is huge, comprising some 97 to 98 percent of the transcription activity in the cell, and specificity depends on low levels of the correct sequences being produced at the right time in the appropriate places. Extreme caution is needed as these RNAi species have the potential to affect the animals adversely, and can also be passed onto humans through food.
RNAi has been used as a tool to study gene function in bovine oocytes. The percentage of active oocytes was increased following RNA i treatment . The sheep nematode parasite, Trichostrongylus , was sensitive to RNAi . RNAi targeted developmental control genes in chicken embryos . RNAi could be used to prevent avian influenza . RNAi specifically silenced genes in fish embryos, and specific gene knockout appeared effective in medaka, zebra fish and r ainbow trout , and was used to silence the myostatin gene leading to giant zebra fish . The tiger frog iridovirus also attacks fish; and RNAi was effective in inhibiting replication of the virus in fish cells .
Somatic gene therapy in farm animals using vectors or naked DNA
Gene therapy has been used in farm animals to transform somatic cells without affecting the germ cells, at least in theory. Retrovirus mediated gene transfer in lungs of living feta sheep has been demonstrated. A Moloney murine leukemia retrovirus vector incorporated a marker gene and either beta-galactosidase, or human interleukin receptor antagonist gene. Gene integration was observed in cells of the airway epithelia . A plasmid vector highly efficient at releasing growth hormone was introduced into the skeletal muscle of pigs using electroporation. The somatic transgenic pigs showed enhanced weight gain and improved body composition at low DNA plasmid dose . An adenovirus vector was used to deliver a human gene angeopoein-1 into the pig heart in animals affected by chronic myocardial ischemia. The implanted gene helped the pigs recover from the condition . A DNA plasmid encoding somatostatin fused with an antigenic protein of a pig reproductive and respiratory syndrome virus induced antibodies to the viral protein and promoted growth in immunized pigs , after a single injection of the plasmid. Continuous infusion of bovine growth hormone releasing factor increased milk production by as much as 46 percent . A vector created from the bovine leukemia virus carried the gene for growth hormone release factor driven by a mouse whey acidic protein promoter, or alternatively, a mouse mammary tumour virus promoter ; and bovine kidney cells were transfected with the vector.
A fowl adenovirus vector was used to insert chicken interferon gene controlled by the fowl adenovirus late promoter and SV40 polyA site . Chickens treated with the recombinant vector showed increased weight gain, and less weight loss when challenged with the parasite causing coccidiosis. A live fowlpox virus vector was constructed carrying a chicken mylomonocytic growth factor gene. Chickens treated with the vector had elevated monocyte levels and a high proportion of active monocytes . Another vector containing chicken interferon, when combined with an antigen (sheep red blood cells), resulted in enhanced antibody response . Using the interferon vector alone increased weight gain and improved resistance to disease.
Recombinant microbes in the rumen
Genetic modification of the microbes in the rumen is a seductive topic. In theory the microbes can be modified to make fodder much more digestible, thus making more efficient use of grazing land. Even though the approach is fairly easy to implement it has not proven effective as yet, because rumen ecology is complex.
All too often, the recombinant microbes proved easy prey for the native protozoa of the rumen. On the other hand, if the recombinant microbes succeed, they may unbalance the ecology of the rumen and cause disease to the animals and to the human beings that use the animal and animal products as food. Genetic engineers should learn much more about the ecology of the rumen.
A recombinant rumen bacterium, Butyrivibrio fibrisolvens , expressing a fungal xylanase gene and erythromycin resistance marker gene was inoculated into a sheep's rumen. The recombinant bacterium disappeared from the rumen of hay-fed sheep within 12 hours of being introduced, but flourished when inoculated into autoclaved rumen fluid; showing that the recombinant bacteria were eliminated by living organisms [71, 72]. The main fibre-digesting bacteria in the rumen, Ruminococcus and Fibrobacter , have proved refractory to genetically modification, leaving only Butyrivibrio that can be modified. The recombinant bacteria were less effective at digesting fibre than the native fibre digesters . Protozoan predation was the main cause of the introduced bacteria disappearing .
The toxin flouroacetate accumulates to high levels in some Australian plants, becoming lethal to grazing sheep. A gene for flouracetate dehalogenase was isolated from the bacterium Moraxella and used to modify Butyrivibrio fibrisolvens . Sheep exposed to flouracetate showed markedly reduced poisoning symptoms after being inoculated with the recombinant bacteria .
In spite of a great deal of effort, recombinant bacteria have not adapted to the rumen. The protozoan residents of the rumen have prevented ready colonization by recombinant bacteria. Interestingly, over 75 percent of the genes for carbohydrate in rumen ciliates originated by horizontal gene from rumen bacteria . The ecology of the rumen has proved refractory to recombinant bacteria. Genes for microbial fibrolytic enzymes have been transferred to probiotic bacteria , however. Such efforts could potentially redesign the food animals' digestive systems. Many of the permanent bacterial residents of the rumen have not yet been cultured. Wild animals may have acquired microbes not seen in domestic animals because they are exposed to more severe dietary conditions. Such microbes and their enzymes may be useful for applications in the future .
C. Outstanding Safety Issues
Food derived from genetically modified animals pose several kinds of health risks, whether heritable or not, and we do not recommend using them as food unless and until these risks have been assessed, and comprehensive studies show that they are safe beyond reasonable doubt.
The health risks of food derived from genetically modified animals come from the specific proteins encoded by the transgenes, from the transgenic nucleic acids and vectors used for genetic modification, and from unintended effects of transgenesis and the cloning procedures used to produce a herd of transgenic animals, as the transgenic animals are often sterile or else do not breed true .
Non-heritable traits, in particular, include potent synthetic antigens for vaccination and powerful immune regulators with well-described side effects, while both heritable and non-heritable traits include growth hormones. The ingestion of foods with growth factors, vaccine antigens or immune regulators is likely to have untoward impacts on the immune system and development of human beings, especially the young.
Many of the genes used to create transgenic food animals are synthetic approximations of the original gene , but deemed, mistakenly, to be “substantially equivalent” to the natural genes. The synthetic genes contain DNA sequences that have never existed in evolution, and by no stretch of the imagination can they be presumed safe.
Synthetic genes are used, first of all, because bacterial genes are not readily translated in animals and plants. Bacteria use different codons for the same amino acids (codon bias), and so the gene sequence has to be modified to allow for that. Transgenes are often composites of different genes. For example, a synthetic transgene was made up of an antibacterial gene from Staphylococcus (lyphostatin) joined to a gene from a Streptococcus bacteriophage (virus of bacteria) encoding endolysin, which dissolves bacteria. The synthetic composite gene was used to modify cows, so they would produce milk that kills bacteria .
One main problem discussed was allergenic potential of the protein in milk. Proponents assured us that the cows modified with the synthetic gene were unlikely to be allergic to the toxin because it is a part of their genome, and thus recognized as self. But they failed to mention that children drinking the milk would not recognize the protein as ‘self', and might well mount immune reactions against the protein, including allergy.
Efforts were made to ‘humanize' transgenic proteins by altering the genes specifying a protein's glycosylation pattern to avoid immune reactions including allergy (allergy sites on proteins often have specific glycosylation), but that approach was only partly effective [81-83]. In view of the recent finding that a normally harmless bean protein turned into a potent immunogen when transferred to pea [82, 83] ( Transgenic Pea that Made Mice Ill ) , there is a case for banning all GM food products until and unless they can be proven safe by adequate tests. This applies all the more so to transgenic animal food products, especially milk, which is consumed predominantly by infants and children.
The profligate use of nucleic acids (RNAs and DNAs) in livestock is a source of deep concern, as it is already well known that they are to varying degrees capable of horizontal gene transfer and recombination with attendant risks of creating new viruses and bacteria that cause diseases, and of triggering cancer by integrating into genome sites that activate oncogenes as gene therapy clinical trials have made all too clear  ( Gene Therapy Woes ) . Similarly, RNAi overload proved lethal to mice ; and it is not safe to presume that the RNAi used to modify animals will not affect those consuming the treated animals.
Comments to the Proposed Draft Guideline for the Conduct of Food Safety Assessment of Foods Derived from Recombinant - DNA Animals
We comment first on matters raised by codex and then some issues not discussed in the Codex food safety assessment.
Codex QUESTIONS FOR AN EXPERT CONSULTATION
Marker and Reporter Genes
What developments have occurred in the development and use of reporter and selectable marker genes?
Selectable markers are commonly employed with both heritable and non-heritable genetic modifications of animals. Common reporter genes are green fluorescent protein, beta-glucuronidase and beta-galatosidase. Selectable markers have included herbicide tolerance genes, although they are not widely used.
Are there non-antibiotic resistance marker or reporter genes that have been demonstrated to be safe to humans in food products, and if so, what are they?
A far as we know, none of the non-antibiotic resistance marker or reporter genes has been demonstrated as safe to humans in food products, while at least one of them, beta-glucuronidase, was found to have amino acid similarities to known allergens  ( Are Transgenic Proteins Allergenic? ).
In prokaryote vectors and in applications such as non-heritable (epigenetic) modifications or in cloning animals from modified tissue cells, antibiotic resistance markers are commonly employed.
With prokaryote expression systems for producing pharmaceuticals , the most common way to achieve selection in the absence of antibiotics is via complementation of an essential gene expressed in a plasmid vector in a strain with a defect in the same essential gene. S everal authors have used the dapD gene, which has a role in the lysine biosynthetic pathway and in cell wall assembly. Cobra Therapeutics proposed a very promising system, the ‘operator repressor titration for antibiotic-free plasmid maintenance', in which plasmid loss induces the down regulation of the es sential dapD gene, and thus the death of the bacteria. Other systems such as pCOR, based on the complementation of an amber mutation, have also been established. Nevertheless, the requirement for a minimal medium for culture means these systems are less likely to be used for production depending on over-expression. The various complementation-based expression systems have the common drawback of being strain dependent, as genetic knockout or modification of an essential gene is not easily transferable from one strain to another and has to be done independently .
A luminescence gene cassette from the Photohabdus luminescens bacterium (an insect pathogen) provides a light emitting tracer gene that can be used with both prokaryote and eukaryote organisms .
When removal of specific DNA sequences is desired, are reliable and safe techniques available to do this on a routine basis?
There is one system, the Crelox, used almost exclusively with both prokaryotes and eukaryotes. Lox sites are signals for site-specific recombination by the Cre recombinase enzyme. A pair of lox site flanks a marker gene or any gene to be removed. The Cre recombinase is driven by a promoter designed to respond to a signal such as an antibiotic or drug. The main problem with its use in higher animals and plants is that the genomes of the higher organism contain cryptic lox sites that are recognized by Cre recombinase, causing chromosomal instability in the genome. The Cre recombinase is effectively genotoxic [93, 94] ( Terminator Recombinase Does Scramble Genomes ) and should not be used.
Are there relevant differences from a food safety perspective between animals with heritable and nonheritable traits, and if so, what are they?
Our review of the non-heritable techniques includes the use of DNA plasmids and viral vectors in both vaccination and in gene therapy to improve meat production or quality. It may appear that the food safety issues of heritable transgenic traits and non-heritable traits are different. Non-heritable traits are mainly based on DNA plasmids, bacterial vectors or viral vectors that do not theoretically integrate into the germline genome, though there is always a small probability that any DNA introduced into an organism may integrate into the germline genome, as the germ cells are not separated from somatic cells by any real physiological barrier that prevents horizontal gene transfer. On account of the unjustified presumption that the foreign genetic material will not be incorporated into the germline, there is a tendency for relaxed regulation, which is equally unjustified.
Many of the recombinant DNA plasmids, bacterial vectors or viral vectors have been subject to clinical trials or even approved with little fanfare and public notification. It has been presumed that the recombinant genes and their protein products are not present in the milk or meat of treated animals but there is little published information to support that assumption, and that is perhaps the main danger.
Are there specific food safety questions (e.g. with regard to types of vectors) that should be considered relative to the assessment of safety of food from animals containing heritable versus non-heritable traits?
We have stressed in our review that the both heritable and non-heritable modifications pose the same kinds of risks, from the products of the transgenes, from the nucleic acids and vectors used in genetic modification, and from unexpected effects of transgenesis, and in the case of heritable modifications, from the cloning procedures.
Non-heritable traits, in particular, include potent synthetic antigens for vaccination and powerful immune regulators, while both heritable and non-hertable traits include growth hormones. These contaminants in foods are likely to have adverse impacts on the immune system and development of human beings, especially the young.
There does not seem to be much published information on the fate of vectors or the transgenes in the treated animals, or the potential for horizontal gene transfer and recombination to create new pathogens. RNAi overload proved lethal to mice; and it is not safe to presume that the RNAi used to modify animals will not affect those consuming the treated animals.
Non-heritable genetic modifications are more threatening than heritable modifications because of its widespread use without the necessary risk assessments. It is also highly likely that meat or milk of recombinant animals will not even be labelled in the market, as they do not fall under the rubric of genetic modification.
The profligate use of nucleic acids (RNAs and DNAs) in livestock is a source of deep concern, as it is already well known that they are to varying degrees capable of horizontal gene transfer and recombination with attendant risks of creating new viruses and bacteria that cause diseases, and of triggering cancer by integrating into genome sites that activate oncogenes.
There have been no studies addressing the unintended changes of genetic modification in transgenic animals or of cloning, which may well create unexpected toxins or immunogens.
Substantial equivalence has no value and is misleading
The Codex Draft Guideline states:” The concept of substantial equivalence is a key step in the safety assessment process.”
We take issue with that statement. “Substantial equivalence” is often used as a starting point to structure the safety assessment of a new food in the most undiscerning and reductionist way. For example, comparisons are made in the gross composition of proteins, carbohydrates and fats, or in amino acid compositions, which generally show little or no difference; and so it allows the proponent to focus on the transgene product(s) only . Moreover, the comparators are completely arbitrary. Instead of comparing the transgenic variety with the variety from which it has been derived, companies have been allowed to compare the transgenic variety with the entire species, or indeed with whole category of foodstuffs from many different species, as in the case of edible oils for example.
Although there have been attempts to improve on establishing substantial equivalence by incorporating profiles of total protein, metabolites and transcripts, the technical hurdles involved in comparing and interpreting patterns are insurmountable, and no official requirements are enforced. In this way, unintended, untoward effects of the modifications will not be revealed unless specific tests other than those used for establishing substantial equivalence are carried out. Examples are tests for toxicity, allergenicity and immunogenicity. Substantial equivalence therefore has nothing to say about the safety of the transgenic food product, and it would be highly misleading to assume it does.
Synthetic genes are not substantially equivalent to the natural
One important fact ignored by the Codex guidelines, which also disposes of the concept of substantial equivalence is that the recombinant animals are constructed using synthetic versions of natural genes that often involve composites of different genes, with different nucleic acid sequences as well as changes in amino acid sequence. The changes in nucleic acid sequence will lead to differences in the recognition of the gene by nucleosomes and histones. Changes in amino acids will give proteins with different conformations that would affect the proteins' interactions with other proteins, and are likely to be regarded as foreign by the host's immune system, as well as by humans eating the transgenic food. Furthermore, these proteins specify potent antigens, growth factors, cytokines or other signal proteins that have potent biological effects and can in no way be regarded as safe.
Transgenes exchanged between closely related species are not substantially equivalent
Even when genes are transferred between closely related species, glycosylation patterns change during protein processing, and could have catastrophic consequences for the human consumer [82, 83] (as discussed in the literature review). Codex should abolish the discredited concept of substantial equivalence once and for all, in recognition that it is highly misleading when used as a key concept in safety assessment.
We do not recommend using genetically modified animals and animal products as food, until and unless they can be proven to be safe by comprehensive safety evaluations, whether the genetic alterations are heritable or non-heritable.
Codex Alimentarius Commission Request for comments to the provisional draft guidelines for the conduct of food safety assessment of foods derived from recombinant DNA animals Food and Agriculture Organization-World Health Organization CL 2006/27-FBT July 2006 http://www.codexalimentarius.net
Houdebine L. Use of transgenic animals to improve human health and animal production. Repro. Dom. Anim 2005, 40, 269-82.
Whitelaw B. Transgenic livestock made easy. Trends in Biotechnology 2004, 22, 157-59.
Oatley JM, de Avila DM, Reeves JJ and McLean DJ. Spermatogenesis and germ cell transgene expression in xenografted bovine testicular tissue. Biol Reprod. 2004, 71(2), :494-501.
Schmidt JA, de Avila JM and McLean DJ. Grafting period and donor age affect the potential for spermatogenesis in bovine ectopic testis xenografts. Biol Reprod. 2006 75(2), 160-6.
Geens M, De Block G, Goossens E, Frederickx V, Van Steirteghem A and Tournaye H. Spermatogonial survival after grafting human testicular tissue to immunodeficient mice. Hum Reprod. 2006, 21(2), 390-6.
Brophy B, Smolenski G, Wheeler T, Wells D, L'Huillier P and Laible G. Cloned transgenic cattle produce milk with higher levels of beta-casein and kappa-casein. Nat Biotechnol. 2003, 21(2), 157-62.
Lai L, Kang JX, Li R, Wang J, Witt WT, Yong HY, Hao Y, Wax DM, Murphy CN, Rieke A, Samuel M, Linville ML, Korte SW, Evans RW, Starzl TE, Prather RS and Dai Y. Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol. 2006, 24(4), 435-6.
Van Cott KE, Lubon H, Gwazdauskas FC, Knight J, Drohan WN and Velander WH. Recombinant human protein C expression in the milk of transgenic pigs and the effect on endogenous milk immunoglobulin and transferrin levels. Transgenic Res. 2001, 10(1), 43-51.
Golovan SP, Meidinger RG, Ajakaiye A, Cottrill M, Wiederkehr MZ, Barney DJ, Plante C, Pollard JW, Fan MZ, Hayes MA, Laursen J, Hjorth JP, Hacker RR, Phillips JP and Forsberg CW. Pigs expressing salivary phytase produce low-phosphorus manure. Nat Biotechnol. 2001, 19(8), 741-5.
Mozdziak PE, Borwornpinyo S, McCoy DW and Petitte JN. Development of transgenic chickens expressing bacterial beta-galactosidase. Dev Dyn. 2003, 226(3), 439-45.
Mozdziak PE, Pophal S, Borwornpinyo S and Petitte JN. Transgenic chickens expressing beta-galactosidase hydrolyze lactose in the intestine. J Nutr. 2003, 133(10), 3076-9.
Ho MW, Lim LC, et al. The Case for a GM Free Sustainable World , Independent Science Panel Report, ISIS and TWN, London & Penang, 2003; republished as GM-Free, Vital Health Publishing, Ridgefield CT, 2004; translated into Chinese, French, German, Portuguese, Spanish and Indonesian.
Logar N and Pollock L. Transgenic is a new policy framework necessary for a new technology? Environmental Science and Policy 2005, 8, 17-27.
Devlin RH, Sundstrom LF and Muir WM. Interface of biotechnology and ecology for environmental risk assessments of transgenic fish. Trends Biotechnol. 2006 24(2), 89-97.
Du SJ, Gong ZY, Fletcher GL, Shears MA, King MJ, Idler DR and Hew CL. Growth enhancement in transgenic Atlantic salmon by the use of an “all fish” chimeric growth hormone gene construct. Biotechnology (N Y ). 1992 , 10(2), 176-81.
Muir WM and Howard RD. Assessment of possible ecological risks and hazards of transgenic fish with implications for other sexually reproducing organisms. Transgenic Res. 2002, 1(2), 101-14.
Muir WM and Howard RD. Possible ecological risks of transgenic organism release when transgenes affect mating success: sexual selection and the Trojan gene hypothesis. Proc Natl Acad Sci U S A . 1999, 96(24), 13853-6.
Cogswell A, Benfey T and Sutterlin A. The hematology of diploid and triploid transgenic Atlantic salmon. Fish Physiology and Biochemistry 2002, 24, 271-7.
Cummins J. Floating transgenic crops in a leaky triploid craft. Science in Society 2003,24,32
Devlin RH, D'Andrade M, Uh M and Biagi CA. Population effects of growth hormone transgenic coho salmon depend on food availability and genotype by environment interactions. Proc Natl Acad Sci U S A. 2004, 101(25), 9303-8.
Devlin R, Johnsson J, Smailus D, Biagt C, Jonsson E and Bjornsson B. Increased ability to compete for food by growth hormone transgenic coho salmon Aquaculture Research 1999, 30, 479-82.
Kisutch.Sundstrom LF, Lohmus M and Devlin RH. Selection on increased intrinsic growth rates in coho salmon, Oncorhynchus . Int J Org Evolution. 2005, 59(7), 1560-9.
Dunham RA, Chatakondi N, Nichols AJ, Kucuktas H, Chen TT, Powers DA, Weete JD, Cummins K and Lovell RT. Effect of rainbow trout growth hormone complementary DNA on body shape, carcass yield, and carcass composition of F1 and F2 transgenic common carp ( Cyprinus carpio ). Biotechnol (NY) . 2002, 4(6), 604-11.
Rahman MA, Mak R, Ayad H, Smith A and Maclean N. Expression of a novel piscine growth hormone gene results in growth enhancement in transgenic tilapia ( Oreochromis niloticus ). Transgenic Res. 1998, 7(5), 357-69.
Razak SA, Hwang GL, Rahman MA and Maclean N. Growth Performance and Gonadal Development of Growth Enhanced Transgenic Tilapia Oreochromis niloticus (L.) Following Heat-Shock-Induced Triploidy. Mar Biotechnol (NY). 1999 Nov;1(6):533-544.
Nam YK, Noh JK, Cho YS, Cho HJ, Cho KN, Kim CG and Kim DS. Dramatically accelerated growth and extraordinary gigantism of transgenic mud loach Misgurnus mizolepis . Transgenic Res. 2001, 10(4), 353-62.
Cortemeglia C and Beitinger T. Projected US distribution of transgenic and wildtype zebra danios, Danio rerio, based on temperature tolerance data. Journal of Thermal biology 2006, 31, 422-8.
Schubbert R, Lettmann C and Doerfler W. Ingested foreign (phage M13) DNA survives transiently in the gastrointestinal tract and enters the bloodstream of mice. Mol Gen Genet. 1994 , 242(5), 495-504.
McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH and Davis HL. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med. 1999, 5(5), 287-300.
Srivastava,I and Lui,M. Gene Vaccines Ann Intern Med 2003,138,550-9
Yokoyama M, Hassett DE, Zhang J and Whitton JL. DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine 1997, 15(5), 553-60.
Oh YK, Kim JP, Yoon H, Kim JM, Yang JS and Kim CK. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther. 2001, 1587-92.
Guo A, Jin Z, Zheng Y, Hai G, Yuan G, Li H and Cai X. Induction of protection against porcine cysticercosis in growing pigs by DNA vaccination. Vaccine 2006 Apr 18; [Epub ahead of print]
Zheng CF, Brownlie R, Huang DY, Babiuk LA and van Drunen Littel-van den Hurk S. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch Virol. 2006, 151(5), 985-93.
Shkreta L, Talbot BG, Diarra MS and Lacasse P. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 2004 Nov 15;23(1):114-26
Mahmood MS, Siddique M, Hussain I, Khan A and Mansoor MK. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide. Vaccine. 2006 May 29;24(22):4838-46
Byon J, Ohira T, Hirono I and Aoki T. Comparative immune responses in Japanese flounder, Paralichthys olivaceus after vaccination with viral hemorrhagic septicemia virus (VHSV) recombinant glycoprotein and DNA vaccine using a microarray analysis. Vaccine 2006, 24 (7), 921-930.
Pasnik DJ and Smith SA. Immunogenic and protective effects of a DNA vaccine for Mycobacterium marinum in fish. Vet Immunol Immunopathol. 2005 Feb 10;103(3-4), 195-206.
Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, Mundt E, Schirrmeier H, Mebatsion T, Mettenleiter TC and Romer-Oberdorfer A. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci U S A. 2006 May 23;103(21):8197-202.
Ju C, Fan H, Tan Y, Liu Z, Xi X, Cao S, Wu B and Chen H. Immunogenicity of a recombinant pseudorabies virus expressing ORF1-ORF2 fusion protein of porcine circovirus type 2. Vet Microbiol. 2005, 109(3-4), 179-90.
Mota RM, Moreira JL, Souza MR, Horta MF, Teixeira SM, Neumann E, Nicoli JR and Nunes AC. Genetic transformation of novel isolates of chicken Lactobacillus bearing probiotic features for expression of heterologous proteins: a tool to develop live oral vaccines. BMC Biotechnol Published online 2006 January 5. doi: 10.1186/1472-6750-6-2.
Cummins J and Ho MW. Genetically modified probiotics should be banned. Microbial Ecology in Health and Disease 2005, 17, 66-68.
Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F and Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006 May 25;441(7092):537-41.
Ho MW. Gene therapy nightmare for mice, could humans be next? Science in Society 31 , 25, 2006.
Paradis F, Vigneault C, Robert C and Sirard MA. RNA interference as a tool to study gene function in bovine oocytes. Mol Reprod Dev. 2005, 70(2), 111-21.
Issa Z, Grant WN, Stasiuk S and Shoemaker CB. Development of methods for RNA interference in the sheep gastrointestinal parasite, Trichostrongylus colubriformis. Int J Parasitol. 2005 Aug;35(9):935-40.
Dai F, Yusuf F, Farjah GH and Brand-Saberi,B. RNAi-induced targeted silencing of developmental control genes during chicken embryogenesis. Dev Biol. 2005, 285(1):80-90.
Li YC, Kong LH, Cheng BZ and Li KS. Construction of influenza virus siRNA expression vectors and their inhibitory effects on multiplication of influenza virus. Avian Dis . 2005, 49(4), 562-73.
Boonanuntanasarn S, Yoshizaki G and Takeuchi T. Specific gene silencing using small interfering RNAs in fish embryos. Biochem Biophys Res Commun. 2003, 310(4), 1089-95.
Acosta J, Carpio Y, Borroto I, Gonzalez O and Estrada MP Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol. 2005 Oct 10;119(4):324-31.
Xie J, Lu L, Deng M, Weng S, Zhu J, Wu Y, Gan L, Chan S and He J. Inhibition of reporter gene and Iridovirus-tiger frog virus in fish cell by RNA interference. Virology. 2005 Jul 20;338(1):43-52.
Pitt BR, Schwarz MA, Pilewski JM, Nakayama D, Mueller GM, Robbins PD, Watkins SA, Albertine KH and Bland RD. Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther. 1995 Jul;2(5):344-50.
Draghia-Akli R, Ellis KM, Hill LA, Malone PB and Fiorotto ML. High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J. 2003 Mar;17(3):526-8.
Shim WS, Li W, Zhang L, Li S, Ong HC, Song IC, Bapna A, Ge R, Lim YT, Chuah SC, Sim EK and Wong P. Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model. J Biomed Sci. 2006 Jul;13(4):579-91.
Li G, Qui H, Han L, Zhou Y, Chen Y, Li J and Tong G. Vaccination of Plasmid DNA Encoding Somatostatin Gene Fused with GP5 Gene of Porcine Reproductive and Respiratory Syndrome Virus Induces Anti-GP5 Antibodies and Promotes Growth Performance in Immunized Pigs Agricultural Sciences in China 2006, 5, 234-240.
Mehigh CS, Elias VD, Mehigh RJ, Helferich WG and Tucker HA. Development of a recombinant bovine leukemia virus vector for delivery of a synthetic bovine growth hormone-releasing factor gene into bovine cells. J Anim Sci. 1993, 71(3), 687-93.
Johnson MA, Pooley C and Lowenthal JW. Delivery of avian cytokines by adenovirus vectors. Dev Comp Immunol. 2000, 24(2-3), 343-54.
Lowenthal JW, York JJ, O'Neil TE, Steven RA, Strom DG and Digby MR. Potential use of cytokine therapy in poultry. Vet Immunol Immunopathol. 1998, 63(1-2), 191-8.
Kobayashi,Y and Yamamoto,M. Factors that limit maintenance of recombinant rumen bacterium in sheep rumen. Animal Science Journal 2002, 73, 131-6.
Gobius KS, Xue GP, Aylward JH, Dalrymple BP, Swadling YJ, McSweeney CS and Krause DO. Transformation and expression of an anaerobic fungal xylanase in several strains of the rumen bacterium Butyrivibrio fibrisolvens. J Appl Microbiol. 2002, 93(1), 122-33.
Krause DO, Bunch RJ, Dalrymple BD, Gobius KS, Smith WJ, Xue GP and McSweeney CS. Expression of a modified Neocallimastix patriciarum xylanase in Butyrivibrio fibrisolvens digests more fibre but cannot effectively compete with highly fibrolytic bacteria in the rumen. J Appl Microbiol. 2001, 90(3), 388-96.
Sharp R, Hazlewood GP, Gilbert HJ and O'Donnell AG. Unmodified and recombinant strains of Lactobacillus plantarum are rapidly lost from the rumen by protozoal predation. J Appl Bacteriol. 1994, 76(2), 110-7.
Gregg K, Hamdorf B, Henderson K, Kopecny J and Wong C. Genetically modified ruminal bacteria protect sheep from fluoroacetate poisoning. Appl Environ Microbiol. 1998, 64(9), 3496-8.
Ricard G, McEwan NR, Dutilh BE, Jouany JP, Macheboeuf D, Mitsumori M, McIntosh FM, Michalowski T, Nagamine T, Nelson N, Newbold CJ, Nsabimana E, Takenaka A, Thomas NA, Ushida K, Hackstein JH and Huynen MA. Horizontal gene transfer from Bacteria to rumen Ciliates indicates adaptation to their anaerobic, carbohydrates-rich environment. BMC Genomics 2006, 7:22. doi: 10.1186/1471-2164-7-22.
Liu JR, Yu B, Liu FH, Cheng KJ and Zhao X Expression of rumen microbial fibrolytic enzyme genes in probiotic Lactobacillus reuteri . Appl Environ Microbiol. 2005, 71(11), 6769-75.
Kobayashi,Y. Inclusion of novel bacteria in rumen microbiology: Need for basic and applied science. Animal Science Journal 2006, 77, 375-85.
Ho MW and Steinbrecher R. Fatal flaws in food safety assessment: Critique of the joing FAO/WHO Biotechnology and Food Safety Report. Journal of Nutritional and Environmental Interactions 1998, 2, 51-84.
Ho MW, Pusztai A, Bordocz S and Cummins J. Are transgenic proteins allergenic? Science in Society 25 , 4-5, 2005.
Prescott VE, Campbell PM, Moore A, Mattes J, Rothenberg ME, Foster PS, Higgins TJV and Hogan SP. Transgenic expression of bean a-amylase inhibitor in peas results in altered structure and immunogenicity. J Agricultural and Food Chemistry 2005, 53, 9023-30.
Sodoyer,R. Expression systems for the production of recombinant pharmaceuticals Biodrugs 2004,18,51-62
MK, Swift S, Hill PJ, Sims CM, Griesmayr G, Bycroft BW, Williams P and Stewart GS. Engineering the luxCDABE genes from Photorhabdus luminescens to provide a bioluminescent reporter for constitutive and promoter probe plasmids and mini-Tn5 constructs. FEMS Microbiol Lett. 1998, 163(2), 193-202.